Difference between revisions of "Teniposide (Vumon)"

Revision as of 23:43, 23 November 2014

Also known as VM-26.

General information

Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.^[1]^[2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

7/14/1992: Initial FDA approval

References

[insert-1] 1.0 ^1.1 Teniposide (Vumon) package insert

[2] Teniposide (Vumon) package insert (locally hosted backup)

[3] Teniposide (Vumon) patient drug information (Chemocare)

[4] Teniposide (Vumon) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 27: / Line 27: @@
 [[Category:Drug index]]
 [[Category:Chemotherapy]]
+[[Category:Intravenous chemotherapy]]
 [[Category:Irritant chemotherapy]]
 [[Category:Topoisomerase inhibitors]]